Edwards Lifesciences Corp (EW)vsGlaukos Corp (GKOS)
EW
Edwards Lifesciences Corp
$85.88
-1.70%
HEALTHCARE · Cap: $49.01B
GKOS
Glaukos Corp
$131.19
+2.72%
HEALTHCARE · Cap: $7.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1043% more annual revenue ($6.30B vs $551.35M). EW leads profitability with a 17.4% profit margin vs -34.3%. GKOS appears more attractively valued with a PEG of 1.64. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
GKOS
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.6%
Fair Value
$252.36
Current Price
$85.88
$166.48 discount
Margin of Safety
-1.2%
Fair Value
$107.76
Current Price
$131.19
$23.43 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Revenue surging 41.2% year-over-year
Earnings expanding 1896.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Expensive relative to growth rate
Trading at 11.4x book value
Weak financial health signals
ROE of -28.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : GKOS
The strongest argument for GKOS centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : GKOS
The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.
Key Dynamics to Monitor
EW profiles as a growth stock while GKOS is a hypergrowth play — different risk/reward profiles.
EW carries more volatility with a beta of 0.87 — expect wider price swings.
GKOS is growing revenue faster at 41.2% — sustainability is the question.
GKOS generates stronger free cash flow (-16M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 44/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Glaukos Corp
HEALTHCARE · MEDICAL DEVICES · USA
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?